BiotechTube
BaroPace

BaroPace

San Francisco, United States· Est.
baropace.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

BaroPace is pioneering blood pressure-regulated therapy (BRT) for cardiac pacemakers, targeting a fundamental shift in pacemaker control. Its PressurePace™ algorithm is designed to dynamically adjust heart rate based on real-time blood pressure, aiming to improve outcomes for patients with HFpEF and hypertension, conditions with massive unmet needs. The company is preparing for a pivotal trial (RelieveHFpEF-III) in 2026 and posits that its technology could enhance quality of life for all pacemaker patients while significantly reducing healthcare costs. If successful, BaroPace's platform could expand the pacemaker market and establish a new standard of care.

Cardiovascular

Technology Platform

PressurePace™ algorithm enabling Blood Pressure-Regulated Therapy (BRT); a closed-loop system that dynamically adjusts cardiac pacemaker heart rate in real-time based on continuous blood pressure measurements.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

BaroPace addresses the massive, untreated HFpEF market (6M US, 23M global patients) with a first-in-class device therapy, potentially establishing a new standard of care.
Its platform could also expand the core pacemaker market by making pacing more physiologic for all patients and open a future path into the enormous drug-resistant hypertension population.

Risk Factors

The company faces high clinical risk as its entire value proposition depends on the success of its unproven pivotal trial.
It must also overcome significant technical challenges in creating a reliable, implantable closed-loop system and later, commercial risks competing against entrenched medtech giants in a conservative physician adoption environment.

Competitive Landscape

BaroPace's direct competitors are the dominant cardiac rhythm management companies (Medtronic, Abbott, Boston Scientific) who could develop similar closed-loop systems. Its indirect competitors are pharmaceutical companies developing drugs for HFpEF. Its key differentiator is its first-mover focus on a blood pressure-regulated pacing algorithm for HFpEF, a novel mechanism of action in the device space.

More companies in Diagnostics & Precision Medicine →More companies in United States →